Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q16526
UPID:
CRY1_HUMAN
Alternative names:
-
Alternative UPACC:
Q16526
Background:
Cryptochrome-1, a pivotal transcriptional repressor, orchestrates the circadian clock, regulating rhythms in gene expression linked to metabolism and behavior. This protein is integral to maintaining physiological balance with environmental cycles, leveraging transcription and translation of core components to generate circadian rhythms. Its role extends to modulating key physiological functions, including sleep, body temperature, and cardiovascular health.
Therapeutic significance:
Cryptochrome-1's involvement in Delayed Sleep Phase Syndrome, through a mutation that enhances its transcriptional repression activity, underscores its potential as a target for therapeutic intervention. Understanding the role of Cryptochrome-1 could open doors to potential therapeutic strategies, particularly in treating circadian rhythm disorders.